<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114568</url>
  </required_header>
  <id_info>
    <org_study_id>8835-039</org_study_id>
    <nct_id>NCT01114568</nct_id>
  </id_info>
  <brief_title>Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)</brief_title>
  <official_title>A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04971729 in Lean To Obese, Otherwise Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the rate and extent of absorption of three oral
      formulations of ertugliflozin (PF 04971729, MK-8835) administered in lean to obese healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin</measure>
    <time_frame>Up to 48 hr. postdose (Up to Day 3 in each dosing period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from Hour 0 to infinity (AUCinf) for ertugliflozin</measure>
    <time_frame>Up to 48 hr. postdose (Up to Day 3 in each dosing period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ertugliflozin</measure>
    <time_frame>Up to 48 hr. postdose (Up to Day 3 in each dosing period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin</measure>
    <time_frame>Up to 48 hr. postdose (Up to Day 3 in each dosing period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ertugliflozin half life (t1/2)</measure>
    <time_frame>Up to 48 hr. postdose (Up to Day 3 in each dosing period)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to 28 days postdose (Up to 49 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary glucose excretion</measure>
    <time_frame>Up to 48 hr. postdose (Up to Day 3 in each dosing period)</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg: tablet→OC slow→OC fast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→tablet→OC slow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→OC slow→tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→tablet→OC fast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→OC fast→tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 10 mg tablet</intervention_name>
    <description>A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.</description>
    <arm_group_label>Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: tablet→OC slow→OC fast</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→tablet→OC slow</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→OC slow→tablet</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→tablet→OC fast</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→OC fast→tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin OC Fast</intervention_name>
    <description>Formulation B) Ertugliflozin 10 mg OC Fast</description>
    <arm_group_label>Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: tablet→OC slow→OC fast</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→tablet→OC slow</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→OC slow→tablet</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→tablet→OC fast</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→OC fast→tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin OC Slow</intervention_name>
    <description>Formulation C) Ertugliflozin 10 mg OC Slow</description>
    <arm_group_label>Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: tablet→OC slow→OC fast</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→tablet→OC slow</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC fast→OC slow→tablet</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→tablet→OC fast</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg: OC slow→OC fast→tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 21 and 65 years, inclusive
             (Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG and clinical laboratory tests). Women must be of non
             childbearing potential

          -  Body Mass Index (BMI) of 18.5 to 35.4 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  An informed consent document signed and dated by the subject.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of screening).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  A positive urine drug screen at Screening or prior to dosing in Period 1.

          -  History of regular alcohol consumption exceeding 14 drinks/week for females or 21
             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relative Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

